کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5664173 1590709 2016 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials
ترجمه فارسی عنوان
درمان های مولکولی جدید در بیماران مبتلا به سرطان پیشرفته هپاتوسلولار در خط دوم درمان: یک شکست واقعی است: نتایج متاآنالیز مبتنی بر ادبیات از آزمایشات تصادفی
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی هماتولوژی
چکیده انگلیسی


- Effective treatments after sorafenib therapy remain an unmet medical need.
- The considered secondary end-points such as PFS and response favoured the use of target agents in the second line of treatment of advanced HCC.
- The incidence of a grade ≥3 adverse event was higher in the arm with molecular therapies.

Several new biological agents have been investigated as second line of treatment in advanced Hepatocellular Cancer (HCC). We performed a meta-analysis to assess the effect of targeted therapies in advanced HCC patients beyond the first line of treatment. A literature-based metaanalysis of randomized controlled trials was undertaken. The primary outcome was the overall survival. The secondary endpoints were the progression-free survival (PFS), the response rate (RR) and disease control rate (DCR) and the safety. Pooled analysis of targeted agents revealed a modest increase in overall survival compared with control arm (Hazard Ratio (HR) = 0.93, 95%CI: 0.83-1.04; P = 0.21). On the counterpart, all the secondary endpoints were in favoured to the targeted agents-based treatment (PFS: HR = 0.68, 95% CI:0.56-0.83; P = 0.0002; RR: 3.50,95% CI 1.81-6.76; P = 0.0002, DCR: RR:1.19, 95% CI 1.06-1.32; P = 0.002). To date, there is a clinical need of a more efficacious second line of therapy in treatment of the advanced HCC. This study showed some activity of the new targeted therapies in second line of treatment in advanced HCC.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Critical Reviews in Oncology/Hematology - Volume 108, December 2016, Pages 62-68
نویسندگان
, , , , , , , ,